Video

Dr. Zurita-Saavedra on Emerging Frontline Therapies in Metastatic HSPC

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.

Amado J. Zurita-Saavedra, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer (HSPC).

Ongoing clinical trials are evaluating PARP inhibitors, AKT inhibitors, and lutetium 177 (177Lu)–PSMA-617 as frontline therapies for men with metastatic HSPC, Zurita-Saavedra explains. Some emerging therapies may have utility in all-comers, whereas others will be reserved for molecularly defined subsets of patients.

Moreover, based on the data that emerged with antiandrogen agents like enzalutamide (Xtandi) and apalutamide (Erleada), it is likely that emerging agents will be combined with these agents to further improve outcomes for patients with metastatic HSPC, Zurita-Saavedra concludes.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD